Drugs / Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013
Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02251288 | May 2015 → Aug 2018 | avian influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02251288 ↗ |
| Modality | Vaccine | “Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013” NCT02251288 ↗ |
| Route | Intramuscular | “Group 1 through Group5 will receive the IM vaccine on Day 1” NCT02251288 ↗ |